Novaliq GmbH Exclusive Interview Released

View Agenda

Ophthalmic Drugs interviews Co-Founder, Chief Innovation Officer, Novaliq GmbH

LONDON, ENGLAND, UNITED KINGDOM, August 21, 2017 /EINPresswire.com/ — SMi Group’s Ophthalmic Drugs conference is thrilled to welcome Bernhard Guenther, Co-Founder, Chief Innovation Officer, Novaliq GmbH onto the speaker panel for 2017.

Bernhard Guenther is the Co-Founder and Chief Innovation Officer at Novaliq. Before taking over the CIO position at the end of last year, he served for 12 years as the CEO of the company. As the CIO he is responsible for the identification and evaluation of new, early-stage development candidates regarding their potential to become part of Novaliq’s innovative product pipeline.

Hear more from Bernhard at Ophthalmic Drugs 2017 as he presents: ‘Aqueous, preservative-free ocular drug delivery technology with unique properties.’

Gain insight into EyeSol Technology, non-aqueous, preservative-free, poorly soluble drugs and ophthalmic drug delivery. Further details are available at: www.ophthalmicdrugs.com/ein6

For those looking to attend there is currently a £300 early-bird saving!

Further information is available at: www.ophthalmicdrugs.com/ein6

SMi Presents the Launch of…
Ophthalmic Drugs
Date: 28th – 29th November 2017
Location: Kensington, London
Website: www.ophthalmicdrugs.com/ein6

Sponsored by: Leica Microsystems | Experimentica

—end—

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Pav Solanki
SMi Group
2078276048
email us here


Source: EIN Presswire

Pain management devices Market Development, market Trend, Industry analysis Segmentation and Forecast to 2023

Global pain management devices market research report, type (stimulators, transcutaneous electrical nerve stimulation devices), application – Forecast Till 2023

Major key Players include Baxter International Inc.,Boston Scientific Corporation,Medtronic Plc,Jude Medical,Bio-Medical Research,Codman and Shurtleff, Inc.”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, August 21, 2017 /EINPresswire.com/ — Market Scenario:
Pain Management is the branch of medical science that deals with the minimizing the pain of the patients. Pain management devices market is driven by increasing number of the patient suffering from different diseases. Increasing aging population and increasing the government efforts in increasing the pain rehabilitation centers has increasing the market. Beside this increasing prevalence of many acute and chronic diseases has also led to increase the market of the pain management devices. On other hand side effects of pain management devices and high cost are the major restraining factors for the growth of the market.

Global pain management device market was $3.58 billion in 2016 which is expected to grow at a CAGR of 7.2 % and reach till $5.81 billion by 2023.

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/1504

Key Players for Global Pain Management Devices Market
• Baxter International Inc. (US),
• Boston Scientific Corporation (US),
• Medtronic Plc (US),
• St. Jude Medical (US),
• Bio-Medical Research (BMR) Ltd. (UK),
• Codman and Shurtleff, Inc. (US),
• Stryker Corporation (US),
• Hospira Inc. (US),
• Smiths Medical (UK),
• Kimberly-Clark Corporation (US),
• DJO Global LLC (US),
• B. Braun Melsungen AG. (Germany)
• Pain Management, Inc (US).

Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Renal dialysis Market Research Report- Forecast To 2027

Segments:
On the basis of types
• Neuromodulation Devices,
• Analgesic Infusion Pumps,
• Deep Brain Stimulators,
• Ablation Devices,
• Neurostimulators
• others.
On the basis of purchase
• over the counter devices
• prescription devices.
On the basis of application
• Cancer pain,
• facial pain,
• neuropathic pain
• others

Study Objectives of Pain management devices Market:
• To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Pain management devices market
• To provide insights about factors affecting the market growth
• To analyze the Pain management devices market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
• To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
• To provide country level analysis of the market with respect to the current market size and future prospective
• To provide country level analysis of the market for segments by type, by mode of purchase, by end users and its sub-segments
• To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

Request Table of Content (TOC), Figures, and Tables @ https://www.marketresearchfuture.com/request-toc/1504

Intended Audience
• Research and Development (R&D) Companies
• Pain Management Device Manufacturing Companies
• Government and Independent Research Laboratories
• Government and Independent Regulatory Authorities
• Contract Research Organizations (CROs)
• Medical Research Laboratories
• Academic Medical Institutes and Universities

Table of Content

1 Introduction
1.1 Definition
1.2 Scope Of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.2.2.1 Assumptions
1.2.2.2 Limitations
1.3 Market Structure:
2 Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power Of Suppliers
4.3 Bargaining Power Of Buyers
4.4 Threat Of New Entrants
4.5 Threat Of Substitutes
4.6 Intensity Of Rivalry
5. Global Pain Management Devices Market, By Device Type
Continue…….

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact:
Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire

Waffor MioSalon.com Ready for International Launch

A Salon & Spa Management Software

India- Based Salon & Spa Management Software expanding their business to US & UK

CHENNAI, TAMIL NADU, INDIA, August 19, 2017 /EINPresswire.com/ — Waffor Miosalon.com One of the main Salon and Spa Software of India has reported that it would be growing their business to Europe and North America. The organization takes pride in making a software intended for Salon and Spa industry which manages to bring new Clients and Retaining existing Client for Salon and Spa.

We Believe Ours is a product which handles the Marketing, Complete POS, Appointment, Staff, Client and Inventory Management intended for the wellness industry, and We are excited to go into the US and European Market says the proprietor and the CEO of WafforMIoSalon.com.

He additionally specified that getting a Salon and Spa Software in these business sectors are enormously costly particularly with the Features we give, that is the thing that we want to address for the Salon and Spa Industry.

The Software is Designed for Both Single to little chain outlet and also for Enterprises Model. They propelled this Software a year ago in April 2016 till then they are taking into account more than 300 salons and Spas in India.

The product computerizes the Client, Staff, Inventory, Incentive and Expense Management with an entire POS arrangement and a Threshold Marketing Tool with an Online Booking Widget for Facebook and Websites guests and significantly more. To find out about this item visit https://www.waffor.com/

Samarth Mishra
Waffor Retail Solutions Pvt. Ltd.
7034317524
email us here


Source: EIN Presswire

With ‘Pill Head’ Petaluma Is the New Hollywood — Again

Pill Head

Pill Head is part of the “Lumaville” series by Daedalus Howell

Daedalus Howell & Karen Hess

Writer-director Daedalus Howell and Producer and production designer Karen Hess.

Photo by Dennis Ferguson.

Pill Head will be film on location in Petaluma, CA.

Creative Team Launches Crowdfunding Campaign for Hometown Feature Film

Our motivation to make this film is not merely to scratch an aesthetic itch — we hope to galvanize our local film community, employ local artists, and add fuel to Petaluma’s creative economy…”

— Daedalus Howell

PETALUMA, CA, UNITED STATES, August 18, 2017 /EINPresswire.com/ — Continuing in the tradition of Hitchcock, Coppola and Lucas, narrative art collective Culture Dept. will make their feature film debut in their native Petaluma, CA.

Comprised of producer and production designer Karen Hess and writer-director Daedalus Howell, the company’s “artsploitation” film Pill Head joins the ranks of The Birds, American Graffiti, Peggy Sue Got Married, Basic Instinct, Scream, Inventing the Abbots, and recent Netflix hit 13 Reasons Why this October when shooting commences following an Indiegogo crowdfunding campaign, which soft-launched last week.

In the film, college student Theda (played by Petaluman Emily Ahrens) is a pill addict who elects to undergo an experimental sleep treatment overseen by a shady professor, Dr. Ashe (played by Petaluman Alia Beeton). When she awakes, she discovers that her treatment has resulted in the psychic ability to see into parallel universes. She seeks out a dodgy metaphysics writer to help her fathom the new power but his council leaves her ill-prepared for the machinations of the professor as the spectre of her own addiction wreak havoc on her sense of self. To break free, she switches identities with another young woman and, as her possible fates unfold before her, she ventures to the brink of sanity to make a defining decision. The path Theda finds herself on could lead to redemption but it may also cost her life. The question is — which one?

An expansion of the darkly comic universe of writer-director Daedalus Howell’s “Lumaville” novels (Quantum Deadline; The Late Projectionist), Pill Head marks the fifth collaboration for Culture Dept., which was aptly described by the Petaluma Argus-Courier as “A pair of local artists with a habit of staging offbeat performance art events in Petaluma” including a postcard exhibit, a pop-up video store, and a fake 80s New Wave band. Whereas Airport Bar, the team’s anti-travel ban performance that recreated an airport bar (“…Their most political statement yet.” — North Bay Bohemian) spoke to international concerns, Pill Head instead focuses its lens on local issues like the burgeoning opioid addiction in small towns like Petaluma.

"'Pill Head' makes a unique and personal statement on a universal theme — redemption — while interrogating the very concept with questions like 'Does it count toward my major?' and 'Is it habit-forming?'" says Howell. "Our motivation to make this film is not merely to scratch an aesthetic itch — we hope to galvanize our local film community, employ local artists, and add fuel to Petaluma’s creative economy while capturing this particular moment in its history."

The Indiegogo campaign can be found at igg.me/at/pillhead or by visiting PillHeadMovie.com.
The official hashtag for the film is #pillheadmovie. Karen Hess and Daedalus Howell are available for interviews. Call (707) 347-9772 or email hello@culturedept.com to schedule.

Daedalus Howell
Culture Dept.
3108692913
email us here

Pill Head | A Film by Daedalus Howell & Karen Hess | Indiegogo


Source: EIN Presswire

LE&RN to host 8th annual New York Walk to Fight Lymphedema & Lymphatic Diseases at Brooklyn Bridge, September 17, 2017

Nicole Faccio with her 2016 NY #LymphWalk team, Brooklyn, NY

Nicole Faccio with her 2016 NY #LymphWalk team, Brooklyn, NY

New York Walk to Fight Lymphedema & Lymphatic Diseases

New York Walk to Fight Lymphedema & Lymphatic Diseases

Nicole Faccio 2016 NY #LymphWalk team Brooklyn Bridge

Nicole Faccio 2016 NY #LymphWalk team Brooklyn Bridge

Hundreds of participants expected; New Yorker and lymphedema activist Nicole Faccio to keynote

I am asking our leaders to invest in quality of life for millions of citizens so people can get proper and affordable care. I am advocating for funding for research, education and, eventually, a cure.”

— Nicole Faccio

NEW YORK, NY, UNITED STATES, August 18, 2017 /EINPresswire.com/ — On Sunday, September 17, beginning at 9am, hundreds of supporters will come together at the base of the Brooklyn Bridge in Cadman Plaza Park, New York City, to kick off the 8th annual New York Walk to Fight Lymphedema & Lymphatic Diseases. The yearly event raises awareness and funding for lymphedema (LE) and lymphatic disease (LD) education, research, and advocacy. Companies will provide LE and LD product demonstrations and information. Speakers will address the progress made and the challenges the community continues to face. Keynote speaker Nicole Faccio will be honored for her ongoing activism at the state level by New York State Senator Martin J. Golden and New York State Assemblymember Linda B. Rosenthal. Darren Wennen, Vice President of Marketing Tactile Medical, will be given the 2017 LE&RN Impact Award.

"I hope my voice increases awareness of lymphedema and lymphatic diseases,” Nicole said. “I am asking our leaders to invest in quality of life for millions of citizens so people can get proper and affordable care. I am advocating for
funding for research, education and, eventually, a cure."

Since her success at last year’s New York #LymphWalk, Nicole has become a leader in New York State's lymphedema movement, making a trip to Albany in March of 2017 for World Lymphedema Day. Nicole’s passion for the cause served to galvanize lawmakers; many have now joined forces with Nicole and LE&RN to pass a lymphedema insurance bill in New York State which would require insurance coverage for equipment, supplies, devices, complex decongestive therapy and out-patient self-management training, and education for the treatment of lymphedema.

To register for the year’s New York #LymphWalk, join a team, form a team, support a team, or become a Virtual Walker, just visit LymphWalk.org. Registration is $20 and each fully registered team member will receive a t-shirt and medal at the end of the Walk. LE&RN thanks National Series sponsors BSN medical (Premier Presenting Sponsor), Tactile Medical (Presenting Sponsor), BioCompression Systems, Juzo, ImpediMed/L-Dex, Eiger, Sigvaris, MediUSA, Herantis, LympheDIVAS, and Lympha Press, as well as local sponsors Lymphedema Products, Norton School, Nesquik, ShechterCare, MME Ink, ILWTI, Wyatt Rehabilitation. Visit LymphWalk.org to find out more about New York #LymphWalk, as well as other events around the country.

About LE&RN
Founded in 1998, the Lymphatic Education & Research Network (formerly LRF) is a 501(c)(3) not-for profit organization whose mission is to fight lymphatic disease and lymphedema through education, research and advocacy. LE&RN provides valuable education resources for the millions of people who suffer from lymphedema and lymphatic disease. LE&RN fosters and supports research that can deepen the medical community's understanding of the lymphatic system. For more information about lymphatic disease or the Lymphatic Education & Research Network, please visit www.LymphaticNetwork.org or call (516) 625-9675.

Laura Farrell
Lymphatic Education & Research Network
(917) 751-7279
email us here


Source: EIN Presswire

NCJFCJ and National Juvenile Defender Center Address LGBTQ Youth and Adolescent Development

Two bench cards released for LGBTQ Youth and Adolescent Development

Judges play a critical role in both ensuring that courts and justice professionals recognize the developmental differences, and to treat LGBTQ-GNC individuals with fairness, dignity, and respect.”

— Judge Anthony (Tony) Capizzi

RENO, NEVADA, UNITED STATES, August 18, 2017 /EINPresswire.com/ — (Reno, Nev.) – The National Council of Juvenile and Family Court Judges (NCJFCJ), in partnership with the National Juvenile Defender Center and the State Justice Institute, recently released two bench cards: one with principles and best practices to ensure that LGBTQ-GNC people in the courtroom are treated with respect, and one addressing adolescent development in delinquency proceedings.

The bench card, Access to Juvenile Justice Irrespective of Sexual Orientation, Gender Identity, and Gender Expression (SOGIE) supports and provides guidance on working with youth or other juvenile court participants that identify as lesbian, gay, bisexual, transgender, queer or questioning, and gender non-conforming (LGBTQ-GNC) youth.

LGBTQ-GNC youth are disproportionality represented in the juvenile justice system. LGBTQ-GNC youth represent five to seven percent of the nation’s youth population, but 20 percent of those are in juvenile detention facilities. 85 percent are youth of color, and 40 percent of girls in detention facilities identify as LGB-GNC.

“Judges are ethically obligated to promote access to justice for all, regardless of race, ethnicity, gender identity, sexual orientation or religion,” said Judge Jay Blitzman, Middlesex Division of the Massachusetts Juvenile Court, who helped draft the bench cards. “With the NCJFCJ’s endorsement of this bench card, it allows us, as judicial leaders, to model good behavior for ourselves, our court personnel, members of the public including the children and families whom we serve.”

The SOGIE bench card encourages judges, and all those subject to the judge’s direction, to be free from personal and extracurricular biases while promoting access to justice for all. It outlines unique considerations at every stage of the case including to: not make assumptions regarding sexual orientation or gender identity; be mindful of the unintended consequences of “outing” a child; supporting an individual’s expression of gender identity by using their preferred name and pronouns of choice; allow transgender and gender non-conforming people to wear clothing that matches their gender identity and expression; among others.

It also outlines recommendations and considerations for specific stages of the case, understanding LGBTQ-GNC terminology, and encourages training and education for judges to ensure all treat LGBTQ-GNC people in the courtroom with respect.

“In many cases for LGBTQ-GNC youth the last stop before hope is lost is the courtroom. Disproportionately represented in the juvenile justice system by the time they come to court these youth may have experience bias and prejudice at home, school and community,” said Judge Ramona Gonzalez, La Cross County Circuit Court. “How a judge speaks to and engages with a youth will not change past adverse experiences but it can be a new beginning where respect, hope, and justice thrive.”

Applying principles of adolescent development in delinquency proceedings encourages judges to understand and learn the developmental differences between youth and adults, and must consider them in judicial decision-making and interactions with youth in court.

“Youth are different from adults and young children are different from older teens,” said Melissa Sickmund, Ph.D., director of the NCJFCJ’s National Center for Juvenile Justice. “The way we understand their behavior and our response to their needs must take those differences into consideration. This bench card gives specifics on how to do that and still hold youth accountable.”

Research shows that adolescents are not just small adults, but are constitutionally different. Adolescents are less culpable and more capable of reform than adults, and are therefore less deserving of the most severe punishments. Adolescents also develop at different rates in social, emotional, physical and cognitive domains.

“Promoting positive youth development and encouraging judges and all actors to utilize research and evidence-based practices reduces recidivism and empowers children,” said Judge Blitzman.

This bench card outlines key principles and research on adolescent development that judges should consider and integrate at each stage of a child's case. Important judicial considerations and practical guidance is offered to help judges translate those principles into practice in the courtroom, which includes sample questions and colloquies that can be utilized in judicial decision-making and interactions with youth in court.

“These bench cards are essential tools to assist juvenile and family court judges and ensure developmentally appropriate, bias-free courtrooms that strengthen a child’s likelihood for success,” said Mary Ann Scali, executive director of the National Juvenile Defender Center. “The NCJFCJ’s endorsement of these cards encourages strong on-the-bench judicial leadership to improve outcomes and increase youth understanding of the court process while ensuring everyone in the courtroom is treated with dignity and respect.”

"The State Justice Institute commends the NCJFCJ and the National Juvenile Defender Center for their continuous effort to provide outstanding educational tools to better inform juvenile and family court judges about the best practices and latest science available on adolescent development,” said Jonathan D. Mattiello, executive director of the State Justice Institute.

The NCJFCJ Board of Directors voted to support and endorse the policies and practices outlined in these two bench cards during their July 2017 annual meeting.

“These resources are part of a line of important informational and policy statements from the NCJFCJ,” said Judge Anthony (Tony) Capizzi, NCJFCJ president. “Judges and judicial leadership play a critical role in both ensuring that courts and justice professionals recognize the developmental differences, supported by the research on adolescent development, between youth and adults and to treat LGBTQ-GNC individuals with fairness, dignity, and respect.”

For more NCJFCJ resolutions and policy statements, visit http://www.ncjfcj.org/about/resolutions-and-policy-statements.

About the National Council of Juvenile and Family Court Judges (NCJFCJ):
Founded in 1937, the Reno, Nev.-based National Council of Juvenile and Family Court Judges, is the nation’s oldest judicial membership organization and focused on improving the effectiveness of our nation’s juvenile and family courts. A leader in continuing education opportunities, research, and policy development in the field of juvenile and family justice, the 2,000-member organization is unique in providing practice-based resources to jurisdictions and communities nationwide.

Chrisie Yabu
KPS3
775-686-7437
email us here


Source: EIN Presswire

Six Research Teams Receive Intermountain-Stanford Grant Award

The collaborative grants provide seed funding for projects aimed at transforming healthcare in multiple fields of medicine

SALT LAKE CITY, UTAH, USA, August 18, 2017 /EINPresswire.com/ — Stanford Medicine and Intermountain Healthcare have announced the recipients of more than $400,000 in seed grants focused on transforming healthcare.

The six projects were chosen from a competitive field of 23 proposals, using a vetting process similar to that used by the National Institutes of Health, which establishes selection criteria and scoring systems.

“The Intermountain-Stanford grant program is part of an exciting collaboration focused on advancing clinical care best practices, education and training, and clinical research in heart disease, cancer, and other conditions. This is the second year of the grant program, in September 2016 seven grants were awarded and those projects are underway. The purpose of the grant award is to spearhead and accelerate research between the two organizations and support innovative projects in research, patient care, and medical education” says Robert W. Allen, Intermountain Healthcare’s Senior Vice President and Chief Operating Officer.

“Our collaboration will foster those scientific discoveries that have potential to improve patient care in both institutions,” says David Larson, MD, MBA, co-chair of the Intermountain-Stanford Collaborative Committee and Stanford University School of Medicine’s Associate Professor of Pediatric Radiology and Associate Chair of Performance Improvement in the Department of Radiology.

The seed grants, up to $75,000 each, were awarded to projects that will be jointly led by principal investigators from Intermountain and Stanford, and will take effect on September 1, 2017.

The six selected projects focus on surgical health services, emergency medicine and electronic decision support, pediatric bronchiolitis, neonatal onset of sepsis, team-based primary care, and infectious disease. Although they’re from diverse clinical areas, all the studies are designed to improve patient care.

The six selected projects:

• Setting a foundation for collaborative surgical health services research at Stanford Health Care, Intermountain Healthcare, and the Veterans Health Administration — Stephen Warner, MD, Orthopedic Surgery, Intermountain Healthcare; Alex Sox-Harris, PhD, MS, Associate Professor (Research) of Surgery, Stanford.

• ePE: Electronic decision support for the diagnosis and treatment of acute pulmonary embolism in the emergency department — Joseph Bledsoe, MD, FACEP, Medical Director Emergency Medicine/Trauma, Intermountain Healthcare; Ian Brown, MD, MS, FAAEM, FACEP, Clinical Assistant Professor, Emergency Medicine, Stanford.

• Optimizing value in bronchiolitis: the bronchiolitis follow-up intervention trial (BeneFIT) — Eric Coon, MD, MS, Pediatric Medicine, Intermountain Primary Children’s Hospital; Alan Schroeder, MD, Associate Chief for Research in the Division of Pediatric Hospital Medicine at Lucile Packard Children’s Hospital Stanford.

• Early detection of neonatal early onset sepsis using the sepsis MetaScore: A genomic analysis of cord blood — Patrick Carroll, MD, MPH, Neonatology, Intermountain Healthcare; Purvesh Khatri, PhD, Assistant Professor (Research) of Medicine (Biomedical Informatics Research-ITI Institute) and of Biomedical Data Science, Stanford.

• Pragmatic Design for Enhanced Team-Based Primary Care — Brenda Reiss-Brennan, PhD, APRN, Behavioral Health Services Director, Intermountain Healthcare; Marcy Winget, PhD, Director, Evaluation Sciences Unit and Clinical Associate Professor in the Division of Primary Care and Population Health, Stanford School of Medicine.

• Repurposing an old drug for a new epidemic: ursodeoxycholic acid and clostridium difficile Infection — Brandon Webb, MD, Infectious Diseases, Intermountain Healthcare; Aruna Subramanian, MD, Clinical Associate Professor, Medicine – Infectious Diseases, Stanford.

“We are privileged to collaborate with the Stanford University School of Medicine, a premier medical school and worldwide leader in science and research,” says Raj Srivastava, MD, MPH, co-chair of the Intermountain-Stanford Collaborative Committee and AVP of Research at Intermountain Healthcare. “We are excited to launch these projects, foster new scientific collaborations focused on improving patient care, and set the stage for the healthcare transformation potential from the Intermountain-Stanford grant program.”

Intermountain Healthcare is a Utah-based, not-for-profit system of 22 hospitals, 180 clinics, a Medical Group with some 1,500 employed physicians, a health plans division called SelectHealth, and other health services. Helping people live the healthiest lives possible, Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs. For more information about Intermountain, visit intermountainhealthcare.org,

Daron Cowley
Intermountain Healthcare
801-442-2834
email us here


Source: EIN Presswire

Vee Technologies in Inc. 5000 list for the third time

Vee Technologies in Inc. 5000 list for the third time

Vee Technologies, a healthcare revenue cycle and business services firm, is an Inc. 5000 company three times in a row.

NEW YORK, NY, USA, August 18, 2017 /EINPresswire.com/ — The healthcare revenue cycle and business services firm scores more banner results.

Inc. Media awarded Vee Technologies another year on the Inc. 5000 list of the fastest growing private American corporations.

•With each year and a larger base of clients and revenue it becomes harder to maintain membership in this exclusive club. A mere one in five companies on the list has made it three times.

“We’re proud to lead the healthcare industry in solving revenue cycle efficiency problems,” said Patrick O’Malley, President of Vee Technologies, Inc. “Clients have leveraged their increased profitability for quality patient care and promoted our contributions with new clients.”

The Vee Technologies team helps hospital networks, physician groups, and insurers improve their net patient revenue and reduce overhead through high-quality, low-cost medical coding and revenue cycle outsourcing. Since 2010, they’ve specialized in efficient solutions for maximizing net patient revenue and accurately documenting value-based care.

Manoj Abraham
Vee Technologies Inc.
4807174995
email us here


Source: EIN Presswire

Acute Myeloid Leukemia Treatment Market is projected to be worth $ 1.2 billion in 2023

Global Acute Myeloid Leukemia Treatment Market Information; by Disease Type (Myeloblastic, Promyeloctic, Myelomonocytic) by Treatment – Forecast to 2023

Major Key Players are Vaso Medical (USA), Tensys Medical Inc. (Netherlands), OrSense Ltd. (Israel),NIMD (Israel), Glucowise (UK), CNSystems Medizintechnik AG (Austria), ”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, August 18, 2017 /EINPresswire.com/ — Market Research Future Publish a New Report on – “Acute Myeloid Leukemia Treatment Market Research Report- Global Forecast to 2023”

Executive Summery
Acute myeloid leukemia (AML) is a cancer of the myeloid blood cells, causing extreme and rapid growth of abnormal white blood cells of the bone marrow. The rapid buildup of abnormal white blood cells causes interference in the production of normal blood cells. AML has a propensity to increase towards age. Replacement of normal bone marrow with cancer cells causes a drop in blood constituents such as red blood cells, platelets, white blood cells etc. which causes symptoms such as fatigue, breathlessness, easy bruising and bleeding, and increased risk of infection. The market driving factors for acute myeloid leukemia (AML) are rise in risk factors such as exposures to carcinogens such as ionizing radiation, chemicals etc. Presence of other blood disorders and genetics is also involved for the higher risk of AML. Other market drivers are increasing number of cancer hospitals, greater awareness, good reimbursement scenario etc. The market constraints are poor cure rates of the present drugs, serious side effects of the drugs etc.

Considering all these factors the market for acute myeloid leukemia treatment is expected to reach $ 1.2 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 5.3 % during 2017-2023.

Acute Myeloid Leukemia Treatment Market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

• Vaso Medical (USA),
• Tensys Medical Inc. (Netherlands),
• OrSense Ltd. (Israel),
• NIMD (Israel),
• Glucowise (UK),
• CNSystems Medizintechnik AG (Austria),
• RSP systems A/S (Denmark)
• GE Healthcare (UK),
• Siemens (Germany),
• Abbott (USA),
• Nemaura (UK)
• Integrity (Israel).

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/3223

Intended Audience
• Global acute myeloid leukemia treatment solutions providers.
• Research and development (R&D) companies
• Market research and consulting service providers
• Academic institutes and universities

Segments:
The global acute myeloid leukemia treatment market is segmented on the basis of disease type. Based on the disease type, the market has been segmented as myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia and megakaryocytic. Based on the treatment, the market has been segmented as chemotherapy, and hematopoietic stem cell transplantation. Chemotherapy is further sub-segmented into induction and post remission.

Taste the market data and market information presented in more than 50 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Acute Myeloid Leukemia Treatment Market Research Report

Regional analysis
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and presence of large hospitals. Asia pacific region will be the fastest region because of large unmet needs which will be led by China and India. The Middle East and Africa market will be led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa is expected to be a laggard due to poor economic and political conditions.

The report for Global Acute myeloid leukemia treatment Market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance.

If you have any special requirements, please let us know and we will offer you the report as you want.

For further information on this report, visit @ https://www.marketresearchfuture.com/reports/acute-myeloid-leukemia-treatment-market-3223

Table of Contents
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.2.2.1 Assumptions
1.2.2.2 Limitations
1.3 Market Structure:
2 Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power Of Suppliers
4.3 Bargaining Power Of Buyers
4.4 Threat Of New Entrants
4.5 Threat Of Substitutes
4.6 Intensity Of Rivalry
5 Global Acute Myeloid Leukemia Treatment Market, By Disease Type
5.1 Myeloblastic
5.2 Promyeloctic
5.3 Myelomonocytic
5.4 Monocytic
5.5 Erythroleukemia
5.6 Megakaryocytic
6 Global Acute Myeloid Leukemia Treatment Market, By By Treatment
6.1 Chemotherapy
6.1.1 Induction
6.1.2 Post Remission
6.2 Hematopoietic Stem Cell Transplantation
7. Global Acute Myeloid Leukemia Treatment Market, By Region
Continued…..

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact Info:
Name: Akash Anand
Organization: Market Research Future
Address: Market Research Future Office No. 524/528,
Phone: +1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire

Percutaneous Coronary Intervention Market is projected To Grow At A CAGR Of 10.8% by 2023

Percutaneous Coronary Intervention Market Info by Stents (Drug-eluting Stents (DES), Bare Metal Stents, Bioresorbable Stents)by Surgery Type – Forecast to 2023

Major Key Players are Abbott Vascular, Svelte Medical, Medtronic Plc., Boston Scientific, Sysmetis, Cardiac Dimensions, Acrostak, Edwards Lifesciences ”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, August 18, 2017 /EINPresswire.com/ — Market Research Future Publish a New Report on – “Global Percutaneous Coronary Intervention Market Research Report – Forecast To 2023”

Executive Summery
Percutaneous Coronary Intervention (PCI) is a non-surgical procedure used to treat narrowing of the coronary arteries of the heart by placing a stent in the contracting artery. PCI uses imaging techniques to guide the stent to the exact location.

The market for PCI is increasing due to rise in risk factors associated with heart diseases such as obesity, smoking and substance abuse, fatty foods etc. The life threatening nature of coronary heart diseases, greater reimbursement to heart diseases, the growth of specialty hospitals etc. are driving the market for PCI. The most critical technological growth factor however is the development of advanced stents such as drug-eluting stents (DES), bare metal stents, bioresorbable stents and the falling cost of these stents.
The regulatory changes in the U.S. is affecting the PCI market positively. For example, the FDI changed the class of standard balloon-tipped angioplasty catheters from Class III medical devices to Class II devices with special controls. Thus companies can now avoid pre-market approval (PMA) process to bring their device to the market. Thus companies will achieve faster clearance for their devices with added advantage of less cost.

The market constraints are the high cost of the procedure, coupled with the risks involved, the low availability of cardiac surgeons, low number of cardiac hospitals etc.

Considering all these factors the market for percutaneous coronary intervention is expected to reach $ 15,769 million by the end of 2023, this market is projected to growing at a CAGR of ~10.8% during 2017-2023.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/3166

Percutaneous Coronary Intervention Market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

Major Key Players

• Abbott Vascular,
• Svelte Medical,
• Medtronic Plc.,
• Boston Scientific,
• Sysmetis,
• Cardiac Dimensions,
• Acrostak,
• Edwards Lifesciences

Intended Audience
• Global Percutaneous coronary intervention solutions providers, manufacturers & suppliers
• Research and development (R&D) companies
• Market research and consulting service providers
• Academic institutes and universities

Test the market data and market information presented through more than 50 market data tables and figures spread over 80 numbers of pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Global Percutaneous coronary intervention Market” Research Report – Forecast to 2023.”

Segments:
The Global percutaneous coronary intervention market is segmented on the basis of stents. Based on the stents, the market has been segmented as drug-eluting stents (DES), bare metal stents and bioresorbable stents. The surgery type segment is further sub segmented into percutaneous coronary intervention (PCI), transcatheter aortic valve implantation (TAVI/TAVR), trans-mitral valve implantation (TMVR). Similarly the cosmetic implants segment is sub segmented into breast augmentation, buttock implants, chin & cheek implants.

Regional analysis
US accounts for the maximum market share of the global percutaneous coronary intervention market and the market is expected to increase continuously in coming years. This can be attributed to increasing pool of awareness and the growing acceptability of percutaneous coronary intervention. Advancing technologies within the percutaneous coronary intervention such as advanced silicone and polymer implants is also driving the market. However there is a definite shift of percutaneous coronary intervention market to Asia pacific and Latin America with the most active part played by medical tourism industry.

The report for Global Percutaneous coronary intervention Market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance.

If you have any special requirements, please let us know and we will offer you the report as you want.

For further information on this report, visit @ https://www.marketresearchfuture.com/reports/percutaneous-coronary-intervention-market-3166

Table of Content
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.2.2.1 Assumptions
1.2.2.2 Limitations
1.3 Market Structure:
2 Research Methodology
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
——-
9 Company Profile
9.1 Abbott Vascular
9.1.1 Overview
9.1.2 Product Overview
9.1.3 Financials
9.1.4 Key Developments
9.2 Svelte Medical
9.2.1 Overview
9.2.2 Product Overview
9.2.3 Financials
9.2.4 Key Developments
9.3 Medtronic Plc.
Continued…..

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact Info:
Name: Akash Anand
Organization: Market Research Future
Address: Market Research Future Office No. 524/528,
Phone: +1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire